Navigation Links
Mindray to Report Second Quarter 2010 Financial Results on August 9, 2010
Date:7/20/2010

SHENZHEN, China, July 20 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will report its financial results for the second quarter ended June 30, 2010 after the U.S. market closes on August 9, 2010. Mindray's management will hold an earnings conference call at 8:00 AM on August 10, 2010 U.S. Eastern Time (8:00 PM on August 10, 2010 Beijing/Hong Kong Time).

    Dial-in details for the earnings conference call are as follows:

    Hong Kong:         +852-3002-1672

    U.S. Toll Free:    +1-866-383-8108

    International:     +1-617-597-5343

    Passcode for all regions:  Mindray

A replay of the conference call may be accessed by phone at the following numbers until August 24, 2010.

    U.S. Toll Free:    +1-888-286-8010

    International:     +1-617-801-6888

    Passcode: 3017 2538

Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://ir.mindray.com .

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://www.mindray.com .

    For investor and media inquiries please contact:

    In the U.S.:

     John Capodanno
     FD
     Tel:   +1-212-850-5705
     Email: john.capodanno@fd.com

     Bryan Armstrong
     FD
     Tel:   +1-312-553-6707
     Email: bryan.armstrong@fd.com

    In China:

     May Li
     Mindray Medical International Limited
     Tel:   +86-755-2658-2518
     Email: ir@mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Medical Provides Mid-Year Update on Product Development
2. Mindray Medical to Present at J.P. Morgan China Conference 2010
3. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
4. Reportlinker Adds European Market for Ventilation and Airway Management Devices
5. Reportlinker Adds Western European Disinfectant Gels and Scrubs Market
6. Reportlinker Adds Global Pharma-biotech Alliance Analysis
7. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
8. International Drug & Explosives Detection Company Identa Corp Reports on New USA Marketing Representative
9. Reportlinker Adds 2010 U.S. Ophthalmologists Assessment of Eye Care Medication Brands
10. New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets
11. K-V Pharmaceutical Company Receives Letter From New York Stock Exchange Regarding Delayed Filing of Its Annual Report on Form 10-K for Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):